Icatibant Teva

Icatibant acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats hereditary angioedema attacks in patients with HAE.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Teva is a bradykinin B2 receptor antagonist indicated for hereditary angioedema (HAE) attacks.

Hereditary angioedema (HAE) attacks: reduces swelling and improves symptoms during acute episodes.

Icatibant Teva may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate headache. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Severe hypersensitivity: rash, pruritus, or angioedema beyond the intended treatment. - Hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Severe injection‑site reaction: necrosis or ulceration. - Thrombocytopenia: low platelet count observed rarely.

Before using Icatibant Teva, consider the following safety measures.

- Hypersensitivity: avoid if the patient has known allergy to icatibant acetate or any excipients. - Cardiovascular monitoring: observe patients with unstable cardiovascular disease for hypotension. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: assess risk versus benefit, as it is unknown whether the drug is excreted in milk. - Renal/hepatic impairment: no specific dose adjustment, but monitor clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva may interact with other medicines that influence bradykinin pathways or cardiovascular status.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Neprilysin inhibitors: can elevate bradykinin and heighten risk of swelling. - Other bradykinin B2 antagonists: concurrent use may lead to unpredictable pharmacodynamics.

Moderate Interactions (Monitor Closely): - NSAIDs: may potentiate hypersensitivity reactions. - Diuretics: monitor blood pressure for additive hypotensive effect. - Antihypertensive agents: observe for excessive blood pressure reduction.